Nexus Biopharma Inc (OTCMKTS:NEXS) sentiments have improved a great deal ever since it transitioned from Plata Resources Inc. The stock is currently trading at highs of $0.437 a share, close to its 52-week high of $0.49 a share. Fueling investor interest in the stock is a string of management changes that have reaffirmed the company’s ability to bring to market its weight-loss treatment.

 Board Appointments

 Bolstering the stock sentiments on the Street is the appointment of Daniel Einhorn to the company’s Scientific & Clinical Advisory board. Mr. Einhorn joins the company as a medical director of the Scripps Whittier Diabetes Institute as well as a Clinical Professor of medicine at UC San Diego.

His years of experience should be invaluable to Nexus Biopharma as it continues to work on the development of a proprietary drug that activates a key metabolic pathway, key to combating weight problems.

“His background and experience will be invaluable as we move our weight loss product candidate into later stage clinical development for treating obesity and type 2 diabetes,” said CEO, Mr. Warren C. Lau.

 Dr. Einhorn joins Jeffrey Pessin who was recently appointed as the chair of the Scientific Advisory. The appointment of Dr. Pessin is especially of importance given that he is a renowned research scientist and discoverer of the weight loss technology that Nexus Biopharma is working on.

 Weight Loss Treatment

By combining the expertise that the two bring to the table, the pharmaceutical company hopes to accelerate the development of the weight loss treatment.  Completed clinical results have already shown that the treatment can be relied upon to reduce fat mass in people struggling with obesity with no loss of lean muscle mass.

 The treatment has also proved to be effective in triggering a higher rate of energy expenditure and increased insulin sensitivity as well as increased fatty acid oxidation. Nexus Biopharma has already filed for Intellectual property protection on a selection of compounds in use on the treatment, ahead of planned FDA human trials.

Nexus Biopharma Inc (OTCMKTS:NEXS) should trade higher in the market on positive results of the expected trials given the impact the treatment could have in the fight against diabetes and obesity.